This article is more than 5 years old. Information may no longer be current.

Cisplatin-based regimens may be more effective than carboplatin-based regimens in urothelial carcinoma

Galsky MD. Ann Oncol. 2012;23:406-410.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Cisplatin-based chemotherapy was linked to better response rates than carboplatin-based regimens in patients with metastatic urothelial carcinoma, according to results of a recent meta-analysis.

The researchers reviewed PubMed articles to compare cisplatin- and carboplatin-based chemotherapy outcomes in 286 patients with metastatic urothelial carcinoma.

Eligible studies were published between 1966 and 2010 and included prospective randomized trials evaluating the two regimens. There were four trials in the analysis.

Due to the unavailability or inconsistency of individual patient data, the primary outcome measures included overall response and complete response rates. Risk ratios also were calculated.

Patients receiving cisplatin-based therapy were more likely to achieve both a complete response (RR=3.54; 95% CI, 1.48-8.49) and an overall response (RR=1.34; 95% CI, 1.04-1.71). No survival data were reported.

Follow HemOncToday.com on Twitter.